Corporate Supporters

ONS Logo with orange banner below that reads "Corporate Council"

The ONS Corporate Council

The ONS Corporate Council is an exclusive, high-level opportunity available to a limited group of industry supporters. In the spirit of true partnership, it was created to reinforce your company’s industry leadership and recognize your essential role in advancing the oncology nursing profession. 

Exclusive Benefits

  • High-level sponsor recognition at our national conferences, ongoing recognition and positioning in ONS communications, and year-round acknowledgement on the ONS website
  • ONS Corporate Council logo to help elevate your communication and promotional efforts
  • Key engagement opportunities with ONS executive leadership.
  • Collaboration opportunities with other Corporate Council members and ONS
  • Priority updates and invitations to ONS sponsored events, ONS news, and ONS initiatives
  • Discounts and complimentary services

The investment for this fully integrated sponsorship opportunity is $140,000 per year.

Please contact for more information. 

ONS Corporate Council Members

AstraZeneca Pharmaceuticals LP

Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, hematology, immunology, cardiovascular and neuroscience. Through the Bristol Myers Squibb Foundation, an independent 501(c)(3) charitable organization, we support community-based programs that promote cancer awareness, screening, care and support among high-risk populations in the United States, as well as China, Brazil and sub-Saharan Africa. Our employees around the world work every day to transform patients’ lives through science.

Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at and follow us on Twitter and LinkedIn. Also find out more about our Clinical Trials and Patient Assistance Program.

Genentech, Inc

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development.

Gilead Oncology

Gilead is creating the future of oncology to help bring more life to people with some of the most difficult-to-treat cancer. We are focused on delivering transformational science, maximizing speed to the patient and being a partner of choice. Visit to learn more.



Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit and follow @Incyte.


Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates, with the potential to improve the treatment of advanced cancers.

Pfizer Oncology

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma. Learn more about our patient assistance program.


Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases. Learn more about our patient assistance program and clinical trials.


Industry Relations Panel

Industry supporters may also join our new Industry Relations Panel, which offers two tiers of support at $50,000 and $25,000 per year. Please contact for more information. 

Industry Relations Panel members receive:

  • Recognition at our national conferences, ongoing recognition and positioning in ONS communications, and year-round recognition on the ONS website
  • Key engagement opportunities with ONS senior leadership
  • Collaboration opportunities with other Industry Relations Panel members and ONS
  • Discounts and complimentary services

Industry Relations Panel Members

Tier 2

Tier 1